A clinical retrospective study of teniposide intra-arterial chemotherapy combined with bevacizumab in treatment of recurrent high-grade glioma

Hu Dan; Pei Yuchun; Zhang Xi; Zhou Changlong

doi:10.13406/j.cnki.cyxb.003446

您当前的位置：

首页 >

文章列表页 >

A clinical retrospective study of teniposide intra-arterial chemotherapy combined with bevacizumab in treatment of recurrent high-grade glioma

Clinical research | 更新时间：2025-10-22

- A clinical retrospective study of teniposide intra-arterial chemotherapy combined with bevacizumab in treatment of recurrent high-grade glioma
- Journal of Chongqing Medical University Vol. 49, Issue 3, Pages: 335-339(2024)
- 作者机构：
  
  1.重庆医科大学第五临床医学院,重庆 400042
  2.陆军军医大学第二附属医院神经外科,重庆 400037
  3.重庆大学附属肿瘤医院外科,重庆 400030
  4.重庆医科大学附属永川医院神经外科,重庆 402177
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003446
  CLC： R739.4
- Received：07 October 2023，
  
  Revised：2023-12-22，
  
  Accepted：04 February 2024，
  
  Published：28 March 2024
- 稿件说明：
移动端阅览
胡丹,裴玉春,张希,等.替尼泊苷动脉化疗联合贝伐珠单抗在复发高级别脑胶质瘤的临床回顾性研究[J].重庆医科大学学报,2024,49(3):335-339.

Hu Dan,Pei Yuchun,Zhang Xi,et al.A clinical retrospective study of teniposide intra-arterial chemotherapy combined with bevacizumab in treatment of recurrent high-grade glioma[J].Journal of Chongqing Medical University,2024,49(3):335-339.
胡丹,裴玉春,张希,等.替尼泊苷动脉化疗联合贝伐珠单抗在复发高级别脑胶质瘤的临床回顾性研究[J].重庆医科大学学报,2024,49(3):335-339. DOI： 10.13406/j.cnki.cyxb.003446.

Hu Dan,Pei Yuchun,Zhang Xi,et al.A clinical retrospective study of teniposide intra-arterial chemotherapy combined with bevacizumab in treatment of recurrent high-grade glioma[J].Journal of Chongqing Medical University,2024,49(3):335-339. DOI： 10.13406/j.cnki.cyxb.003446.

摘要

目的

探索替尼泊苷超选动脉化疗联合贝伐珠单抗在复发高级别脑胶质瘤治疗的临床疗效和安全性。

方法

79例复发高级别脑胶质瘤患者按治疗方法的不同，分为试验组37例（替尼泊苷动脉化疗联合贝伐珠单抗治疗）和对

照组42例（贝伐珠单抗单药治疗），比较两组患者脑胶质瘤维持治疗后的客观缓解率、疾病控制率及不良反应率，评估O

-甲基鸟嘌呤-DNA甲基转移酶基因启动子甲基化状态对两组患者疾病控制率的影响。

结果

试验组和对照组的客观缓解率分别为43.2%和21.4%（

=0.038），疾病控制率分别为78.4%和54.8%（

=0.027）。试验组在轻度消化道反应（

=0.044）、头痛（

=0.044）及白细胞减少（

=0.026）的不良反应发生率高于对照组。试验组年龄小于60岁人群的疾病控制率较对照组明显增加（

0.05）。

结论

在高级别脑胶质瘤维持治疗中，替尼泊苷超选动脉化疗联合贝伐珠单抗的疗效优于贝伐珠单抗单药治疗，值得临床进一步推广。

Abstract

Objective

To investigate the efficacy and safety of teniposide superselective intra-arterial chemotherapy combined with bevacizumab in the treatment of recurrent high-grade glioma.

Methods

According to the treatment method，79 patients with recurrent high-grade glioma were divided into experimental group with 37 patients （teniposide intra-arterial chemotherapy combined with bevacizumab） and control group with 42 patients （bevacizumab monotherapy）. The two groups were compared in terms of objective response rate，disease control rate，and the incidence rate of adverse reactions，and the impact of the gene promoter methylation status of O

-methylguanine-DNA methytransferase on disease control rate was analyzed.

Results

The objective response rate was 43.2% in the experimental group and 21.4% in the control group（

=0.038），and the disease control rate was 78.4% in the experimental group and 54.8% in the control group（

=0.027）. Compared with the control group，the experimental group had significantly higher incidence rates of the adverse reactions such as mild gastrointestinal reactions（

=0.044），headache（

=0.044），and leucopenia（

=0.026）. Compared with the control group，the experimental group had a significantly higher disease control rate in the population aged

60 years（

0.05）.

Conclusion

Teniposide superselective intra-arterial chemotherapy combined with bevacizumab has better efficacy than bevacizumab monotherapy in the treatment of recurrent high-grade glioma and thus holds promise for further clinical application.

关键词

Keywords

references

Luo CK ， Xu SC ， Dai G ， et al . Tumor treating fields for high-grade gliomas [J ] . Biomed Pharmacother ， 2020 ， 127 ： 110193 ．

Wang X ， Lu J ， Guo GC ， et al . Immunotherapy for recurrent glioblastoma：practical insights and challenging prospects [J ] . Cell Death Dis ， 2021 ， 12 （ 4 ）： 299 ．

Smith SJ ， Tyler BM ， Gould T ， et al . Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste [J ] . Clin Cancer Res ， 2019 ， 25 （ 16 ）： 5094 - 5106 ．

Tomar MS ， Kumar A ， Srivastava C ， et al . Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance [J ] . Biochim Biophys Acta Rev Cancer ， 2021 ， 1876 （ 2 ）： 188616 ．

Sun YC ， Wang J ， Guo CC ， et al . MiR-181b sensitizes glioma cells to teniposide by targeting MDM2 [J ] . BMC Cancer ， 2014 ， 14 ： 611 ．

Jo J ， Wen PY . Antiangiogenic therapy of high-grade gliomas [J ] . Prog Neurol Surg ， 2018 ， 31 ： 180 - 199 ．

Annakib S ， Rigau V ， Darlix A ， et al . Bevacizumab in recurrent WHO grades II-III glioma [J ] . Front Oncol ， 2023 ， 13 ： 1212714 ．

Eisenhauer EA ， Therasse P ， Bogaerts J ， et al . New response evaluation criteria in solid tumours：revised RECIST guideline （version 1.1） [J ] . Eur J Cancer ， 2009 ， 45 （ 2 ）： 228 - 247 ．

Le Rhun E ， Preusser M ， Roth P ， et al . Molecular targeted therapy of glioblastoma [J ] . Cancer Treat Rev ， 2019 ， 80 ： 101896 ．

Weller M ， van den Bent M ， Preusser M ， et al . EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood [J ] . Nat Rev Clin Oncol ， 2021 ， 18 （ 3 ）： 170 - 186 ．

Gilbert MR ， Pugh SL ， Aldape K ， et al . NRG oncology RTOG 0625：a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma [J ] . J Neurooncol ， 2017 ， 131 （ 1 ）： 193 - 199 ．

Xu YN ， Guan HJ ， Yu KF ， et al . Efficacy and safety of pharmacotherapy for recurrent high-grade glioma：a systematic review and network meta-analysis [J ] . Front Pharmacol ， 2023 ， 14 ： 1191480 ．

McBain C ， Lawrie TA ， Rogozińska E ， et al . Treatment options for progression or recurrence of glioblastoma：a network meta-analysis [J ] . Cochrane Database Syst Rev ， 2021 ， 5 （ 1 ）： CD013579 ．

van der Meulen M ， Chahal M ， Mason WP . The value of etoposide for recurrent glioma [J ] . Can J Neurol Sci ， 2023 ： 1 - 4 ．

Bergman D ， Modh A ， Schultz L ， et al . Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma [J ] . J Neurooncol ， 2020 ， 148 （ 2 ）： 353 - 361 ．

Yakkala PA ， Penumallu NR ， Shafi S ， et al . Prospects of topoisomerase inhibitors as promising anti-cancer agents [J ] . Pharmaceuticals ， 2023 ， 16 （ 10 ）： 1456 ．

Dhawan S ， Patil CG ， Chen C ， et al . Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas [J ] . Cochrane Database Syst Rev ， 2020 ， 1 （ 1 ）： CD009229 ．

D’Amico RS ， Khatri D ， Reichman N ， et al . Correction to：super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood-brain barrier disruption：where are we now，and where we are going [J ] . J Neurooncol ， 2020 ， 147 （ 2 ）： 279 ．

Muldoon LL ， Soussain C ， Jahnke K ， et al . Chemotherapy delivery issues in central nervous system malignancy：a reality check [J ] . J Clin Oncol ， 2007 ， 25 （ 16 ）： 2295 - 2305 ．

Joshi S ， Ellis JA ， Ornstein E ， et al . Intraarterial drug delivery for glioblastoma mutiforme：will the phoenix rise again? [J ] . J Neurooncol ， 2015 ， 124 （ 3 ）： 333 - 343 ．

Theodotou C ， Shah AH ， Hayes S ， et al . The role of intra-arterial chemotherapy as an adjuvant treatment for glioblastoma [J ] . Br J Neurosurg ， 2014 ， 28 （ 4 ）： 438 - 446 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical value of Golgi protein 73 in primary biliary cholangitis

Advances in the diagnosis and treatment of diabetic peripheral neuropathy

Interpretation of updated key points in the American Diabetes Association’s 2025 Standards of Care in Diabetes

Interpretation of the China Guidelines for the Prevention and Treatment of Diabetes （2024 Edition）

Research advances in the influencing factors for exposure keratopathy and related treatment methods

Related Author

Tang Dijiao

Yu Xuefei

Chen Pu

Wang Yanping

Zou Lin

Chen Zhongpei

Li Zhenhan

Yu Xiaoxia

Related Institution

Department of Laboratory Medicine，The First Affiliated Hospital of Chongqing Medical University

Department of Endocrinology，Chongqing Traditional Chinese Medicine Hospital

Department of Endocrinology，Chongqing Armed Police Corps Hospital

Department of Endocrinology， The People’s Hospital of Yubei District of Chongqing

Department of Endocrinology， The People's Hospital of Yubei District of Chongqing city

⁰